Impact BioMedical Inc. (IBO) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Impact BioMedical Inc.

    AMEX: IBO · Real-Time Price · USD
    0.65
    -0.01 (-2.23%)
    At close: Oct 01, 2025, 3:57 PM
    0.64
    -1.10%
    After-hours: Oct 01, 2025, 05:44 PM EDT

    Impact BioMedical Income Statement

    Financials in CAD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 2.33M 1.03M 1.07M n/a
    Cost of Revenue
    		 n/a n/a n/a n/a
    Gross Profit
    		 2.33M 1.03M 1.07M n/a
    Operating Income
    		 551.66K -28.03K 497.15K -3.83M
    Interest Income
    		 5.69K n/a n/a 31.82K
    Pretax Income
    		 -2.05M -2.39M -10.5M -3.87M
    Net Income
    		 -2.05M -2.39M -10.5M -3.87M
    Selling & General & Admin
    		 1.02M 1.72M 4.57M 3.73M
    Research & Development
    		 91.77K 9.21K 409.31K 63.2K
    Other Expenses
    		 670.05K -668.6K -127.55K n/a
    Operating Expenses
    		 1.78M 1.06M 5.82M 3.86M
    Interest Expense
    		 168.95K 118.13K 67.74K 15.01K
    Selling & Marketing Expenses
    		 n/a n/a n/a 200.98K
    Cost & Expenses
    		 1.78M 1.06M 5.82M 3.86M
    Income Tax Expense
    		 n/a n/a -59.8K 15.01K
    Shares Outstanding (Basic)
    		 232.5M 191.3M 185.64M 125.19M
    Shares Outstanding (Diluted)
    		 232.5M 191.3M 185.64M 125.19M
    EPS (Basic)
    		 -0.01 -0.01 -0.06 -0.03
    EPS (Diluted)
    		 -0.01 -0.01 -0.06 -0.03
    EBITDA
    		 -1.54M -1.98M -4.61M -3.76M
    EBIT
    		 -1.88M -2.27M n/a -3.83M
    Depreciation & Amortization
    		 343.46K 296.05K 266.4K 69.86K

    Add to Watchlist